Evidence map›Paper›PMID 41911471›Full record

ReviewBioconjugate chemistry2026

Peptide-Based PROTACs: Transitioning from Static Paradigm to a Dynamic Landscape within Targeted Protein Degradation.

Xinchen Lu, Quanyin Hu

Abstract readReview
In one paragraph

Review in Bioconjugate chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Xinchen LuPharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin 53703, United States.
Quanyin HuPharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin 53703, United States.ORCID 0000-0003-2946-1655

Funding

Engineering ferritin degrader-encapsulated platelets for post-surgical TNBC treatmentR01EB035992 · NIBIB · UNIVERSITY OF WISCONSIN-MADISON · PI Quanyin Hu · 2024 to 2026
$1.7M
Improving the platelet-mediated immune checkpoint inhibitor delivery for treating triple-negative breast cancerR01CA288851 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Quanyin Hu · 2025 to 2026
$1.3M
NCI NIH HHS R01 CA288851NIBIB NIH HHS R01 EB035992
6 · The paper itself

Abstract

Proteolysis-targeting chimeras (PROTACs) are becoming a powerful therapeutic strategy, enabling event-driven elimination of disease-causing proteins. While small-molecule PROTACs have advanced rapidly, their broader application is constrained by limited target scope, dependence on druggable binding pockets, and susceptibility to the hook effect. Peptide-based PROTACs (pPROTACs) have gained attention as a complementary platform, leveraging the specificity, modularity, and structural adaptability of conjugates to expand the range of degradable targets, including proteins traditionally considered undruggable. This review summarizes recent advances in classical pPROTAC design and conjugation strategies and highlights emerging nonclassic and deconstructive pPROTAC architectures that reassemble functional modules through supramolecular or genetic approaches. Further, bioPROTAC, as a protein-based degrader enabled by genetic encodability, is discussed. Together, these strategies position pPROTACs as an evolving class of targeted protein degradation agents that complement small-molecule approaches.

Indexed as

PeptidesProteinsProteolysisAnimalsHumansProteolysis Targeting ChimeraPeptidesProteinsProteolysis Targeting Chimera

Identifiers

PMID41911471
PMCPMC13088029

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.